Niacin ( DrugBank: Niacin )


3 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease2
78Hypopituitarism1
265Lipodystrophy1

6. Parkinson disease


Clinical trials : 2,298 Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03808961
(ClinicalTrials.gov)
January 1, 202016/1/2019Niacin for Parkinsons DiseaseNAPS: Niacin for Parkinsons DiseaseParkinson's DiseaseDietary Supplement: Niacin;Dietary Supplement: Niacinamide;Other: PlaceboVA Office of Research and DevelopmentNULLRecruiting35 YearsN/AAll100N/AUnited States
2NCT03462680
(ClinicalTrials.gov)
September 28, 201622/2/2018GPR109A and Parkinson's Disease: Role of Niacin in Outcome MeasuresGPR109A and Parkinson's Disease: Role of Niacin in Outcome MeasuresParkinson's DiseaseDietary Supplement: niacin;Other: placeboVA Office of Research and DevelopmentNULLCompleted35 YearsN/AAll47N/AUnited States

78. Hypopituitarism


Clinical trials : 494 Drugs : 385 - (DrugBank : 49) / Drug target genes : 44 - Drug target pathways : 100
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01237041
(ClinicalTrials.gov)
July 1, 20116/11/2010Free Fatty Acids, Body Weight, and Growth Hormones Secretion in ChildrenFree Fatty Acids, Body Weight, and Growth Hormone Secretion in ChildrenObesity;Short Stature;Growth Hormone DeficiencyDrug: Niacin First;Drug: Placebo First;Drug: Dose-Establishing Study 1 Niacin 250mg;Drug: Dose-Establishing Study 1 Niacin 500mg;Drug: Dose-Establishing Study 2 Niacin 500mgEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NULLTerminated7 Years14 YearsAll37Phase 1/Phase 2United States

265. Lipodystrophy


Clinical trials : 116 Drugs : 170 - (DrugBank : 61) / Drug target genes : 26 - Drug target pathways : 97
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00246376
(ClinicalTrials.gov)
January 200427/10/2005Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or DyslipidemiaDiet/Exercise, Niacin, Fenofibrate for HIV LipodystrophyCardiovascular Diseases;Heart Diseases;HIV Infections;Hyperlipidemia;Hypertriglyceridemia;Insulin Resistance;AtherosclerosisBehavioral: Diet;Behavioral: Exercise;Drug: Niacin;Drug: Fenofibrate;Other: PlacebosBaylor College of MedicineNational Heart, Lung, and Blood Institute (NHLBI);Legacy Community Health CenterCompleted18 Years65 YearsAll221N/AUnited States